797047-20-2Relevant academic research and scientific papers
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy
Perola, Emanuele,Stamos, Dean,Grillot, Anne-Laure,Ronkin, Steven,Wang, Tiansheng,Letiran, Arnaud,Tang, Qing,Deininger, David D.,Liao, Yusheng,Tian, Shi-Kai,Drumm, Joseph E.,Nicolau, David P.,Tessier, Pamela R.,Mani, Nagraj,Grossman, Trudy H.,Charifson, Paul S.
, p. 2177 - 2181 (2014/05/06)
A series of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV were identified and optimized to mid-to-low nanomolar potency against a variety of bacteria. However, in spite of seemingly adequate exposure achieved upon IV administration,
BENZIMIDAZOLE DERIVATIVES AS GYRASE INHIBITORS
-
Page/Page column 75, (2010/11/27)
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and composition
Gyrase inhibitors and uses thereof
-
Page 71, (2008/06/13)
The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordi
